AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21606568 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (16 mg/day)
Number of subjects: 0
Study 21606568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21606568 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 0
Study 16107168 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect immunofluorescence
Number of subjects: 0
Study 16107168 — intervention group
Group type: COMPARATOR
Intervention: Calcofluor white fluorescence
Number of subjects: 0
Study 12131085 — intervention group
Group type: EXPERIMENTAL
Intervention: J-pouch
Number of subjects: 88
Study 12131085 — intervention group
Group type: COMPARATOR
Intervention: Coloplasty pouch (CP)
Number of subjects: 88
Study 9844096 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 20
Study 9844096 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaerobic training
Number of subjects: 20
Study 9844096 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 7914409 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 46
Study 7914409 — intervention group
Group type: COMPARATOR
Intervention: Other disease-modifying antirheumatic drugs (DMARDs)
Number of subjects: 46
Study 2644747 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.075 mg/kg i.v.
Number of subjects: 16
Study 2644747 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 16
Study 811427 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (sublingual or oral)
Number of subjects: 37
Study 811427 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 37
Study 31711104 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice (8 oz per day)
Number of subjects: 261
Study 31711104 — intervention group
Group type: COMPARATOR
Intervention: Placebo (8 oz per day, matched constituents of pomegranate juice except for pomegranate polyphenols)
Number of subjects: 261
Study 28732453 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (sunitinib, pazopanib, axitinib, sorafenib)
Number of subjects: 220
Study 28732453 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events of special interest treatment (pharmacologic and/or nonpharmacologic)
Number of subjects: 220
Study 28732453 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitor dose management
Number of subjects: 220
Study 28732453 — intervention group
Group type: EXPERIMENTAL
Intervention: Neither treatment nor dose management
Number of subjects: 220
Study 28732453 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for hypertension
Number of subjects: 220
Study 28732453 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for fatigue
Number of subjects: 220
Study 28732453 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis for adverse events
Number of subjects: 220
Study 28732453 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment discontinuation due to adverse events
Number of subjects: 220
Study 26323018 — intervention group
Group type: EXPERIMENTAL
Intervention: GEL (67.2 ± 7.2 g · h‐1 of CHO)
Number of subjects: 9
Study 26323018 — intervention group
Group type: COMPARATOR
Intervention: LIQ (67.8 ± 4.2 g · h‐1 of CHO)
Number of subjects: 9
Study 26323018 — intervention group
Group type: EXPERIMENTAL
Intervention: GEL
Number of subjects: 9
Study 26323018 — intervention group
Group type: COMPARATOR
Intervention: LIQ
Number of subjects: 9
Study 24423751 — intervention group
Group type: EXPERIMENTAL
Intervention: Stérimar Original
Number of subjects: 18
Study 24423751 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinus Rinse
Number of subjects: 18
Study 24423751 — intervention group
Group type: COMPARATOR
Intervention: Emcur
Number of subjects: 18
Study 24423751 — intervention group
Group type: EXPERIMENTAL
Intervention: Stérimar Original and Sinus Rinse
Number of subjects: 18
Study 22466379 — intervention group
Group type: EXPERIMENTAL
Intervention: Power wheelchairs
Number of subjects: 28
Study 19643656 — intervention group
Group type: EXPERIMENTAL
Intervention: Large amplitude of oscillations (forces between 50 and 200N)
Number of subjects: 30
Study 19643656 — intervention group
Group type: EXPERIMENTAL
Intervention: Small amplitude of oscillations (150N‐200N)
Number of subjects: 30
Study 19643656 — intervention group
Group type: EXPERIMENTAL
Intervention: Quasi-static (maintained at 200N)
Number of subjects: 30
Study 19643656 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific intervention mentioned)
Number of subjects: 30
Study 18785289 — intervention group
Group type: EXPERIMENTAL
Intervention: Music during colonoscopy
Number of subjects: 722
Study 18785289 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 722
Study 15892401 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 695
Study 15892401 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 695
Study 15892401 — intervention group
Group type: COMPARATOR
Intervention: Transfused patients (Control)
Number of subjects: 695
Study 15892401 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa and Routine care (Control)
Number of subjects: 695
Study 12592245 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride 60 mg/day
Number of subjects: 0
Study 12592245 — intervention group
Group type: COMPARATOR
Intervention: Continuous-combined hormone therapy (conjugated equine estrogen 0.625 mg/day plus medroxyprogesterone acetate 2.5 mg/day)
Number of subjects: 0
Study 12592245 — intervention group
Group type: COMPARATOR
Intervention: Continuous-combined hormone therapy
Number of subjects: 0
Study 12592245 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study 10566120 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg q.i.d. for four weeks
Number of subjects: 37
Study 10566120 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets q.i.d. for four weeks
Number of subjects: 37
Study 8606557 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey sponsored by medical practice
Number of subjects: 0
Study 8606557 — intervention group
Group type: COMPARATOR
Intervention: Survey sponsored by university
Number of subjects: 0
Study 8606557 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 1952005 — intervention group
Group type: EXPERIMENTAL
Intervention: oesophageal detector device
Number of subjects: 100
Study 6119103 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 25
Study 6119103 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg
Number of subjects: 25
Study 6119103 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol durules 200 mg
Number of subjects: 25
Study 6119103 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release oxprenolol 160 mg
Number of subjects: 25
Study 6119103 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release oxprenolol 320 mg
Number of subjects: 25
Study 6119103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 30753355 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine
Number of subjects: 0
Study 30753355 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Number of subjects: 0
Study 30753355 — intervention group
Group type: COMPARATOR
Intervention: Control (Nongametocytocidal drugs)
Number of subjects: 0
Study 28973682 — intervention group
Group type: EXPERIMENTAL
Intervention: Pituitary GammaKnife radiosurgery (160 Gy delivered in pituitary gland) associated with standards of care
Number of subjects: 0
Study 28973682 — intervention group
Group type: COMPARATOR
Intervention: Standards of care for pain according to recommendations
Number of subjects: 0
Study 28973682 — intervention group
Group type: EXPERIMENTAL
Intervention: Pituitary GammaKnife radiosurgery
Number of subjects: 0
Study 26981576 — intervention group
Group type: COMPARATOR
Intervention: Maraviroc (intervention in a randomized, placebo-controlled trial)
Number of subjects: 267
Study 26981576 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group receiving placebo)
Number of subjects: 267
Study 26981576 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (general findings from the study)
Number of subjects: 267
Study 25155992 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium (16 g total fiber/day)
Number of subjects: 189
Study 25155992 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose (CMC) (16 g total fiber/day)
Number of subjects: 189
Study 25155992 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum arabic (GA) (16 g total fiber/day)
Number of subjects: 189
Study 25155992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 25155992 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 189
Study 22429436 — intervention group
Group type: EXPERIMENTAL
Intervention: Case scenario based seminar (intervention)
Number of subjects: 73
Study 22429436 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care genetic counsellor (intervention)
Number of subjects: 73
Study 22429436 — intervention group
Group type: EXPERIMENTAL
Intervention: GC-managed appointments (intervention)
Number of subjects: 73
Study 22429436 — intervention group
Group type: COMPARATOR
Intervention: Control group (no seminar)
Number of subjects: 73
Study 22429436 — intervention group
Group type: COMPARATOR
Intervention: Secondary care genetic counsellor (control)
Number of subjects: 73
Study 20610931 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole 200 mg per os TID
Number of subjects: 0
Study 20610931 — intervention group
Group type: COMPARATOR
Intervention: Standard azoles (fluconazole 400 mg per os OD, itraconazole 200 mg per os BID)
Number of subjects: 0
Study 17693284 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 105
Study 17693284 — intervention group
Group type: COMPARATOR
Intervention: Ticarcillin/clavulanate
Number of subjects: 105
Study 15644007 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 101
Study 15644007 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 101
Study 15644007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 12373041 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-Ox-LDL titer on admission
Number of subjects: 39
Study 12373041 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-Ox-LDL titer one month after admission
Number of subjects: 39
Study 12373041 — intervention group
Group type: COMPARATOR
Intervention: anti-Ox-LDL titer on admission in patients with occluded IRA
Number of subjects: 39
Study 12373041 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-Ox-LDL titer on admission in patients who underwent thrombolytic therapy
Number of subjects: 39
Study 12219893 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading background information about the issues to be discussed in the text material
Number of subjects: 0
Study 12219893 — intervention group
Group type: COMPARATOR
Intervention: No background information
Number of subjects: 0
Study 12219893 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading background information about text sources
Number of subjects: 0
Study 9833600 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg once daily for 6 weeks
Number of subjects: 25
Study 9833600 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50 mg once daily for 6 weeks
Number of subjects: 25
Study 8026247 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetropium bromide 10 mg intravenously over 3 min
Number of subjects: 20
Study 8026247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8026247 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetropium bromide
Number of subjects: 20
Study 2596070 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant complex (vitamins C, E, and A) administered preoperatively
Number of subjects: 197
Study 335687 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (2 X 2 tablets per 5 mg daily) and Trichlormethiazidum (1 X 1 tablet per 4 mg daily)
Number of subjects: 74
Study 30878103 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ultrasound (2 MHz pulsed‐wave ultrasound for 120 min)
Number of subjects: 676
Study 30878103 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound (control group)
Number of subjects: 676
Study 28856858 — intervention group
Group type: EXPERIMENTAL
Intervention: HIFU treatment with SonoVue at 1 minute after administration
Number of subjects: 206
Study 28856858 — intervention group
Group type: COMPARATOR
Intervention: HIFU treatment only (control group)
Number of subjects: 206
Study 26324372 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg once per day for 2 years
Number of subjects: 973
Study 26324372 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 years
Number of subjects: 973
Study 26324372 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib in EGFRm-positive subgroup
Number of subjects: 973
Study 26324372 — intervention group
Group type: COMPARATOR
Intervention: Placebo in EGFRm-positive subgroup
Number of subjects: 973
Study 26324372 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 973
Study 26324372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 973
Study 23490328 — intervention group
Group type: EXPERIMENTAL
Intervention: ESBA105 6.4 mg (cohort III)
Number of subjects: 79
Study 23490328 — intervention group
Group type: EXPERIMENTAL
Intervention: ESBA105 3.2 mg (cohorts II and IV)
Number of subjects: 79
Study 23490328 — intervention group
Group type: EXPERIMENTAL
Intervention: ESBA105 (cohorts I, II, and IV)
Number of subjects: 79
Study 23490328 — intervention group
Group type: EXPERIMENTAL
Intervention: ESBA105 (cohort IV)
Number of subjects: 79
Study 23490328 — intervention group
Group type: COMPARATOR
Intervention: ESBA105
Number of subjects: 79
Study 21609280 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR) alone
Number of subjects: 46
Study 21609280 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction with resistance training (CR+RT)
Number of subjects: 46
Study 21609280 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 46
Study 19358394 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy
Number of subjects: 20
Study 19358394 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 20
Study 16428576 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraabdominal pressure of 15 mm Hg (group A)
Number of subjects: 9
Study 16428576 — intervention group
Group type: COMPARATOR
Intervention: Intraabdominal pressure of 8-10 mm Hg (group B)
Number of subjects: 9
Study 15213563 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose intra-partum nevirapine in combination with standard antiretroviral therapy
Number of subjects: 891
Study 11685612 — intervention group
Group type: EXPERIMENTAL
Intervention: Burr hole strict closed-system drainage (SCD); n=56
Number of subjects: 101
Study 11685612 — intervention group
Group type: COMPARATOR
Intervention: Burr hole closed-system drainage with irrigation (CDI); n=45
Number of subjects: 101
Study 9059217 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.1 mg kg‐1
Number of subjects: 8
Study 9059217 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 8
Study 8322005 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing triclosan/silicone oil
Number of subjects: 33
Study 8322005 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 33
Study 3550162 — intervention group
Group type: EXPERIMENTAL
Intervention: EC/IC bypass with continuing medical care
Number of subjects: 1377
Study 3550162 — intervention group
Group type: COMPARATOR
Intervention: Medical care alone
Number of subjects: 1377
Study 30601429 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic technique under general anesthesia (LG)
Number of subjects: 57
Study 30601429 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgery under combined anesthesia (OGE)
Number of subjects: 57
Study 30601429 — intervention group
Group type: COMPARATOR
Intervention: Open surgery under general anesthesia (OG)
Number of subjects: 57
Study 30408810 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-salt (LS) diet (3.0 g/day of NaCl)
Number of subjects: 44
Study 30408810 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salt (HS) diet (18.0 g/day of NaCl)
Number of subjects: 44
Study 30408810 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salt (HS) diet
Number of subjects: 44
Study 30408810 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-salt (LS) diet
Number of subjects: 44
Study 30408810 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-salt (LS) and High-salt (HS) diets
Number of subjects: 44
Study 26526662 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes with albuminuria (≥ 30 mg/24 h)
Number of subjects: 60
Study 26526662 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes with normoalbuminuria (<30 mg/24 h)
Number of subjects: 60
Study 26526662 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic controls
Number of subjects: 60
Study 24102685 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic reference cleansers
Number of subjects: 24
Study 24102685 — intervention group
Group type: COMPARATOR
Intervention: Reference cleansers
Number of subjects: 24
Study 24102685 — intervention group
Group type: COMPARATOR
Intervention: Commercial skin cleansers
Number of subjects: 24
Study 22103428 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (2.86 mg kg(‐1))
Number of subjects: 7
Study 22103428 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol-lidocaine (1 mg kg(‐1) and 2.46 mg kg(‐1))
Number of subjects: 7
Study 22103428 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (1 mg kg(‐1))
Number of subjects: 7
Study 20602575 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise plus paroxetine 40 mg/day (n=21)
Number of subjects: 75
Study 20602575 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise plus pill placebo (n=20)
Number of subjects: 75
Study 20602575 — intervention group
Group type: EXPERIMENTAL
Intervention: relaxation plus paroxetine (n=17)
Number of subjects: 75
Study 20602575 — intervention group
Group type: COMPARATOR
Intervention: relaxation plus pill placebo (n=17)
Number of subjects: 75
Study 18048817 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic and prostate radiotherapy
Number of subjects: 444
Study 18048817 — intervention group
Group type: COMPARATOR
Intervention: Prostate radiotherapy only
Number of subjects: 444
Study 16079905 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory minute ventilation (MMV) for 2 hours
Number of subjects: 20
Study 16079905 — intervention group
Group type: COMPARATOR
Intervention: Synchronized intermittent mandatory ventilation (SIMV) for 2 hours
Number of subjects: 20
Study 16079905 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory minute ventilation (MMV)
Number of subjects: 20
Study 16079905 — intervention group
Group type: COMPARATOR
Intervention: Synchronized intermittent mandatory ventilation (SIMV)
Number of subjects: 20
Study 12571295 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional ankle brace
Number of subjects: 100
Study 12571295 — intervention group
Group type: COMPARATOR
Intervention: Below-the-knee cast
Number of subjects: 100
Study 9869717 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic hemoclip method
Number of subjects: 124
Study 9869717 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic saline-epinephrine (HSE) injection
Number of subjects: 124
Study 9869717 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (hemoclip + HSE)
Number of subjects: 124
Study 8762418 — intervention group
Group type: EXPERIMENTAL
Intervention: Yuyang powder (YYP)
Number of subjects: 200
Study 8762418 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (Control)
Number of subjects: 200
Study 2065700 — intervention group
Group type: EXPERIMENTAL
Intervention: Liv.52
Number of subjects: 8
Study 2065700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6134430 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (900-2400 mg/day, median 1700)
Number of subjects: 15
Study 6134430 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden (6-18 mg/day, median 12)
Number of subjects: 15
Study 6134430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3577451 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocolysis with Fenoterol
Number of subjects: 0
Study 3577451 — intervention group
Group type: EXPERIMENTAL
Intervention: Short TEDI (72 hours or less)
Number of subjects: 0
Study 3577451 — intervention group
Group type: EXPERIMENTAL
Intervention: Long TEDI (more than 72 hours)
Number of subjects: 0
Study 3577451 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of obstetrical parameters between short and long TEDI groups
Number of subjects: 0
Study 29214460 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow restriction at 120 mmHg
Number of subjects: 0
Study 29214460 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow restriction at 200 mmHg
Number of subjects: 0
Study 29214460 — intervention group
Group type: COMPARATOR
Intervention: Control group with 20 min recovery
Number of subjects: 0
Study 29214460 — intervention group
Group type: COMPARATOR
Intervention: Control group with 5 min recovery
Number of subjects: 0
Study 26882222 — intervention group
Group type: EXPERIMENTAL
Intervention: MobileKids Monster Manor (MKMM)
Number of subjects: 42
Study 25340801 — intervention group
Group type: EXPERIMENTAL
Intervention: PXL01 in sodium hyaluronate
Number of subjects: 138
Study 25340801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 23863047 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled CoolSense device
Number of subjects: 177
Study 23863047 — intervention group
Group type: COMPARATOR
Intervention: Non-cooled device (placebo)
Number of subjects: 177
Study 19952830 — intervention group
Group type: COMPARATOR
Intervention: Water trial (500 mL of plain water)
Number of subjects: 19